IDEXX Laboratories stock edges higher as valuation stays rich

Published on 09/16/2026 at 12:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock traded around USD 510 as of September 15, 2026, leaving the shares near their 52-week low but below prior highs. Recent data show a market capitalization of about USD 40 billion and a premium earnings multiple.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories, Inc. stock (ISIN US45168D1046) is trading around the USD 510 mark on the New York Stock Exchange as of September 15, 2026, keeping the diagnostics specialist in a high-valuation bracket despite a pullback from earlier peaks in its 52-week range.

Price level and recent trading range

Per price data from a recent market overview, IDEXX Laboratories shares closed at USD 509.56 on September 14, 2026, on their primary listing in the United States, with the price snapshot cited again near USD 509.56 in a long-term stock selection article that uses closing prices as of September 14, 2026, 3:59 p.m. Eastern Time.

Additional quote information from a stock portal shows IDEXX Laboratories trading at USD 510.73 with a daily gain of 0.23 percent as of September 15, 2026, and a reported market capitalization of roughly USD 40.236 billion in the diagnostics and research industry, placing the current price only modestly above the low end of a 52-week range but still well below the high end.

Long-term growth and valuation context

A recent long-horizon analysis of core holdings highlights IDEXX Laboratories as a defensive quality stock, noting that company revenue grew from USD 3.22 billion to USD 4.30 billion over the period considered and that free cash flow reached USD 1.06 billion, with the shares trading on a price-to-earnings ratio around 35.2 times and an estimated fair-value upside of 2.2 percent based on closing prices as of September 14, 2026.

That comparison underscores a clear double-digit expansion in top-line performance, with revenue up approximately 33.5 percent from USD 3.22 billion to USD 4.30 billion over the multi-year span while free cash flow growth to USD 1.06 billion supports the premium valuation multiples investors currently assign to the diagnostics franchise.

Stock positioning for investors

With IDEXX Laboratories stock changing hands slightly above USD 509 on September 14, 2026, and around USD 510.73 on September 15, 2026, against a 52-week range that stretches from about USD 500.61 at the low to USD 769.98 at the high, the shares remain much closer to the lower boundary of that range than to the prior peak, even as the market capitalization stands near USD 40 billion.